Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5826700 | European Journal of Pharmacology | 2016 | 11 Pages |
Abstract
In mice and dogs, gemigliptin prevented the degradation of active glucagon-like peptide-1 by DPP-4 inhibition, which improved glucose tolerance by increasing insulin secretion and reducing glucagon secretion during an oral glucose tolerance test. The long-term anti-hyperglycemic effect of gemigliptin was evaluated in diet-induced obese mice and high-fat diet/streptozotocin-induced diabetic mice. Gemigliptin dose-dependently decreased hemoglobin A1c (HbA1c) levels and ameliorated β-cell damage. In conclusion, gemigliptin is a potent, long-acting, and highly selective DPP-4 inhibitor and can be a safe and effective drug for the long-term treatment of type 2 diabetes.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Sung-Ho Kim, Eunsoo Jung, Min Kyung Yoon, O. Hwan Kwon, Dal-Mi Hwang, Dong-Wook Kim, Junghyun Kim, Sun-Mee Lee, Hyeon Joo Yim,